Pneumococcal Vaccine Approach Successful in Tests

Author: Children's Hospital Boston
Published: 2011/02/16 - Updated: 2022/06/01
Topic: Immunization and Vaccines - Publications List

Page Content: Synopsis Introduction Main

Synopsis: New vaccine candidate that is potentially cheaper and able to protect against any pneumococcal strain.

The current study, led by Malley and Kristin Moffit, MD of Children's and Todd Gierahn, Ph.D., and Jessica Flechtner, Ph.D., of Genocea Biosciences, began by evaluating a comprehensive library of S. pneumoniae proteins, seeking those that stimulated TH17 cells in mice. They identified specific pneumococcal proteins that activated TH17 cells and used them to make a new vaccine formulation.

In further collaboration with PATH, the researchers will refine and test the most promising formulation in preclinical studies. If the vaccine proves to be effective and safe, the group will prepare an Investigational New Drug (IND) application to the FDA to begin clinical trials.

Introduction

Pneumococcus (Streptococcus pneumoniae) accounts for as much as 11 percent of mortality in young children worldwide. While successful vaccines like Prevnar® exist, they are expensive and only work against specific pneumococcal strains, with the risk of becoming less effective as new strains emerge. Through a novel discovery approach, researchers at Children's Hospital Boston and Genocea Biosciences, Inc., in collaboration with the international nonprofit organization PATH, developed a new vaccine candidate that is potentially cheaper and able to protect against any pneumococcal strain.

Main Item

Tested in mice, the protein-based vaccine successfully inhibited S. pneumoniae from establishing a foothold in the body, the researchers report in the February 17 issue of Cell Host & Microbe.

The current multivalent conjugate pneumococcal vaccines work by inducing people to make antibodies against the sugars on the bacterium's outer capsule. The antibodies then help fight off the development of disease after the bacteria have colonized the body. But these vaccines are complex to manufacture, requiring separate individual components for sugars produced by multiple pneumococcal strains. Since pneumococci can make more than 90 different types of sugars, the vaccines may become less effective over time.

The new protein-based vaccine takes a different approach. Based on close to a decade of research at Children's Hospital Boston and utilizing Genocea's novel vaccine discovery technology developed at Harvard Medical School, it stimulates a group of cells in the body known as TH17 cells. These cells provide natural immunity to pneumococcal infection by clearing the bacteria from the surfaces of the upper respiratory tract where the infection starts.

Six years ago, Richard Malley, MD, and colleagues showed in mice that while antibodies against surface proteins can protect against pneumococcal disease, there is another mechanism of protection that doesn't require antibodies: the body has natural defenses that act as security guards, preventing the bacteria from becoming squatters in the upper respiratory tract. More recently, they showed that this protection is centered in TH17 cells and the production of the chemical messenger IL-17A.

The current study, led by Malley and Kristin Moffit, MD of Children's and Todd Gierahn, Ph.D., and Jessica Flechtner, Ph.D., of Genocea Biosciences, began by evaluating a comprehensive library of S. pneumoniae proteins, seeking those that stimulated TH17 cells in mice. They identified specific pneumococcal proteins that activated TH17 cells and used them to make a new vaccine formulation.

When live mice were immunized with these antigens, they showed near-complete protection from S. pneumoniae upper respiratory tract colonization. These same antigenic proteins also potently stimulated human TH17 cells from healthy adult volunteers, causing them to secrete IL-17A.

"The next steps, already in motion, are to optimize the formulation of this vaccine, confirm its efficacy and safety in animals, and then proceed to human trials," says Malley.

In further collaboration with PATH, the researchers will refine and test the most promising formulation in preclinical studies. If the vaccine proves to be effective and safe, the group will prepare an Investigational New Drug (IND) application to the FDA to begin clinical trials.

Unlike existing conjugate vaccine components, the new pneumococcal protein-based vaccine antigens are common to all strains of S. pneumoniae. The researchers hope that a combination of 3 to 5 antigens will protect against pneumococcal colonization and disease from all strains, thereby providing comprehensive immunity with a universal vaccine that would be significantly less complex and expensive to manufacture.

Malley believes that an approach focusing on stimulating TH17 cells or IL-17A secretion may also be effective in providing protection against other pathogens such as Staphylococcus aureus, Mycobacterium tuberculosis, or Listeria monocytogenes.

"By combining advances in molecular biology, immunology, and bioinformatics, the strategy we use at Genocea allows comprehensive, rapid, and unbiased screens of every protein produced by an infectious agent to identify the most effective T cell-stimulating antigens," says Flechtner. "We look forward to our continued collaboration and the development of an improved pneumococcal vaccine."

Attribution/Source(s):
This quality-reviewed publication was selected for publishing by the editors of Disabled World (DW) due to its significant relevance to the disability community. Originally authored by Children's Hospital Boston, and published on 2011/02/16 (Edit Update: 2022/06/01), the content may have been edited for style, clarity, or brevity. For further details or clarifications, Children's Hospital Boston can be contacted at childrenshospital.org. NOTE: Disabled World does not provide any warranties or endorsements related to this article.

Explore Similar Topics

- Protect or prevent? A practicable framework for the dilemmas of COVID-19 vaccine prioritization.

- Vaccine-skeptical content that is not being flagged by Facebook is potentially lowering users intentions to get vaccinated by 2.3 percentage points.

Citing Information and Page References

Disabled World (DW) is a comprehensive online resource providing information and news related to disabilities, assistive technologies, and accessibility. Founded in 2004 our website covers a wide range of topics, including disability rights, healthcare, education, employment, and independent living, with the goal of supporting the disability community and their families.

Cite This Page (APA): Children's Hospital Boston. (2011, February 16 - Last revised: 2022, June 1). Pneumococcal Vaccine Approach Successful in Tests. Disabled World (DW). Retrieved February 7, 2025 from www.disabled-world.com/medical/immunization/pneumococcal.php

Permalink: <a href="https://www.disabled-world.com/medical/immunization/pneumococcal.php">Pneumococcal Vaccine Approach Successful in Tests</a>: New vaccine candidate that is potentially cheaper and able to protect against any pneumococcal strain.

While we strive to provide accurate and up-to-date information, it's important to note that our content is for general informational purposes only. We always recommend consulting qualified healthcare professionals for personalized medical advice. Any 3rd party offering or advertising does not constitute an endorsement.